NCT06880757View on ClinicalTrials.gov

177Lu-FAP-2286 Treatment in Urethelial Neoplasms: Utility and Safety as a Novel Treatment.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

January 1, 2028

Study Completion Date

June 1, 2028

Conditions
Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
Interventions
OTHER

Radionuclide treatment with Lu-177 FAPI

Systemic radionuclide treatment with Lu-177 FAPI

All Listed Sponsors
collaborator

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER

lead

Ankara University

OTHER